Current support is provided by an SBIR (Small Business Innovation Research) administrative supplement grant from NIDCRR44 DE024456. NIDCR HIV grant that evolved out of NIDCR grant U01 DE017855 for the development of a confirmatory point-of- care diagnostic for HIV. We gratefully acknowledge Silke Weisenburger(PEPperPRINT Heidelberg, Germany) for her technical assistance and kind support. We also thank NYU Langone Medical Center for the LI-COR Odyssey Imaging System.

These data are a part of an ongoing research study conducted at New York University College of Dentistry and were approved by the Institutional Review Board of the New York University School of Medicine, IRB # H10-01894. Clinical samples used in this study were de-identified samples used previously for diagnosis and with permission from the Wadsworth Center of New York State Department of Health, Albany, NY.
1. Installing the ZIKV High-density Peptide Microarray Slide in a specific Incubation Tr...

<ol>
	<li>Kelser, E. A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Meet+dengue's+cousin.">Meet dengue's cousin.</a> Zika. Microbes Infect. 18 (3), 163-166 (2016).</li><li>Musso, D., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Detection+of+Zika+virus+in+saliva.">Detection of Zika virus in saliva.</a> J Clin Virol. 68, 53-55 (2015).</li><li>Siqueira, W. L., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Oral+Clinical+Manifestations+of+Patients+Infected+with+Zika+Virus.">Oral Clinical Manifestations of Patients Infected with Zika Virus.</a> Oral Health. , (2016).</li><li>Duarte, G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Challenges+of+Zika+Virus+Infection+in+Pregnant+Women.">Challenges of Zika Virus Infection in Pregnant Women.</a> Rev Bras Ginecol Obstet. 38 (6), 263-265 (2016).</li><li>Buus, S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=High-resolution+mapping+of+linear+antibody+epitopes+using+ultrahigh-density+peptide+microarrays.">High-resolution mapping of linear antibody epitopes using ultrahigh-density peptide microarrays.</a> Mol Cell Proteomics. 11 (12), 1790-1800 (2012).</li><li>Kouzmitcheva, G. A., Petrenko, V. A., Smith, G. P. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Identifying+diagnostic+peptides+for+lyme+disease+through+epitope+discovery.">Identifying diagnostic peptides for lyme disease through epitope discovery.</a> Clin Diagn Lab Immunol. 8 (1), 150-160 (2001).</li><li>Hamby, C. V., Llibre, M., Utpat, S., Wormser, G. P. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Use+of+Peptide+library+screening+to+detect+a+previously+unknown+linear+diagnostic+epitope:+proof+of+principle+by+use+of+lyme+disease+sera.">Use of Peptide library screening to detect a previously unknown linear diagnostic epitope: proof of principle by use of lyme disease sera.</a> Clin Diagn Lab Immunol. 12 (7), 801-807 (2005).</li><li>t Hoen, P. A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Phage+display+screening+without+repetitious+selection+rounds.">Phage display screening without repetitious selection rounds.</a> Anal Biochem. 421 (2), 622-631 (2012).</li><li>Townend, J. E., Tavassoli, A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Traceless+Production+of+Cyclic+Peptide+Libraries+in+E.+coli.">Traceless Production of Cyclic Peptide Libraries in E. coli.</a> ACS Chem Biol. 11 (6), 1624-1630 (2016).</li><li>Turchetto, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=High-throughput+expression+of+animal+venom+toxins+in+Escherichia+coli+to+generate+a+large+library+of+oxidized+disulphide-reticulated+peptides+for+drug+discovery.">High-throughput expression of animal venom toxins in Escherichia coli to generate a large library of oxidized disulphide-reticulated peptides for drug discovery.</a> Microbial Cell Factories. 16 (1), 6 (2017).</li><li>Carmona, S. J., Sartor, P. A., Leguizamon, M. S., Campetella, O. E., Aguero, F. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Diagnostic+Peptide+Discovery:+Prioritization+of+Pathogen+Diagnostic+Markers+Using+Multiple+Features.">Diagnostic Peptide Discovery: Prioritization of Pathogen Diagnostic Markers Using Multiple Features.</a> Plos One. 7 (12), e50748 (2012).</li><li>Lagatie, O., Van Dorst, B., Stuyver, L. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Identification+of+three+immunodominant+motifs+with+atypical+isotype+profile+scattered+over+the+Onchocerca+volvulus+proteome.">Identification of three immunodominant motifs with atypical isotype profile scattered over the Onchocerca volvulus proteome.</a> PLoS Negl Trop Dis. 11 (1), e0005330 (2017).</li><li>Basile, A. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Development+and+validation+of+an+ELISA+kit+(YF+MAC-HD)+to+detect+IgM+to+yellow+fever+virus.">Development and validation of an ELISA kit (YF MAC-HD) to detect IgM to yellow fever virus.</a> J Virol Methods. 225, 41-48 (2015).</li><li>Madden, T. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+BLAST+Sequence+Analysis+Tool.">The BLAST Sequence Analysis Tool.</a> The NCBI Handbook. , (2013).</li><li>Services, U. S. D. o. H. a. H. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=.">.</a> Biosafety in Microbiological and Biomedical Laboratories (BMBL). , (2009).</li><li>Pellois, J. P., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Individually+addressable+parallel+peptide+synthesis+on+microchips.">Individually addressable parallel peptide synthesis on microchips.</a> Nat Biotech. 20 (9), 922-926 (2002).</li><li>Stafford, P., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Physical+Characterization+of+the+"Immunosignaturing+Effect".">Physical Characterization of the "Immunosignaturing Effect".</a> Mol Cell Proteomics. 11 (4), (2012).</li><li>Gardner, T. J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Functional+screening+for+anti-CMV+biologics+identifies+a+broadly+neutralizing+epitope+of+an+essential+envelope+protein.">Functional screening for anti-CMV biologics identifies a broadly neutralizing epitope of an essential envelope protein.</a> Nat Commun. 7, (2016).</li><li>Nixon, C. E., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Identification+of+protective+B-cell+epitopes+within+the+novel+malaria+vaccine+candidate+P.+falciparum+Schizont+Egress+Antigen-1.">Identification of protective B-cell epitopes within the novel malaria vaccine candidate P. falciparum Schizont Egress Antigen-1.</a> Clin Vaccine Immunol. , (2017).</li></ol>

The authors have nothing to disclose.

We designed a protocol utilizing a high-density peptide microarray containing the entire Zika virus protein sequence (French Polynesian strain). The microarray was manufactured by printing 3,423 different overlapping linear peptides. Each peptide was 15 amino acids and varied by only one residue from its nearest neighbor in the sequence (i.e., 14 residue overlap). Although shorter overlaps can be printed, epitope mapping is more precise with longer overlaps. Each peptide was printed in duplicate to increase reli...

Zika virus (ZIKV) diagnosis based on clinical symptoms is challenging because it shares vectors, geographic distribution, and symptoms with Dengue and Chikungunya virus infection1. Given the risk for adverse pregnancy outcomes in women infected with ZIKV during pregnancy, it is important to distinguish between the 3 viruses. Although the current molecular diagnostic tests are specific, they are only useful in blood or saliva during the relatively short period of acute infection2,3. Serological assays are essential for diagnosis outside this initial period of infection4.
The development of a ZIKV specific serological assay is challenging for two reasons: first, the Zika antigens that the human immune system responds to are not currently known; and second, conserved flaviviruses amino acid sequences induce antibody cross-reactivity. Our objective was to discover unique ZIKV specific peptides to be used in diagnostics. Different approaches have been developed to screen peptide libraries covering entire proteins including phage, bacterial, and yeast surface display5,6,7,8,9,10. Our strategy was to use a high-density peptide microarray that permits rapid and inexpensive high-throughput serological screenings11,12 and subsequently the identified peptides can be used to improve current serological assays for detection of ZIKV infection.
This protocol enables the discovery of Zika virus specific diagnostic peptides using a high-density peptide microarray (Figure 1). The high-density peptide microarray was produced using the peptide laser printing technology. The entire ZIKV protein sequence consisting of 3,423 amino acid residues based on the French Polynesian strain (GenBank: KJ776791.2), was printed on a standard glass slide in blocks of 15 linear residues with an overlap of 14 amino acid residues in duplicate for a total of 6,846 peptide spots. In addition to the entire Zika protein sequence peptides, the microarray utilizes Influenza hemagglutinin (HA) peptides for internal controls.
A Zika validated positive serum sample obtained from Wadsworth Center (Albany, NY), was used to identify specific Immunoglobulin M (IgM) and Immunoglobulin G (IgG) reactive peptides. After incubating with the sample overnight, the microarray was stained with a secondary fluorochrome conjugated antibody (anti-human IgM or anti-human IgG), and analyzed on a microarray scanner. Quantification of spot intensities and peptide annotation was performed with a specific software provided by the same company that manufactured the microarray.

<table>
	<tbody>
		<tr>
			<td>PEPperCHIP Custom Peptide Microarray</td>
			<td>PEPperPRINT</td>
			<td>PPC.001.001</td>
			<td>Custom peptide micarray: our microarray contains the entire Zika virus protein sequence</td>
		</tr>
		<tr>
			<td>PEPperCHIP incubation tray 3/1</td>
			<td>PEPperPRINT</td>
			<td>PPC.004.001</td>
			<td></td>
		</tr>
		<tr>
			<td>PEPperCHIP Staining Kit (680 nm) (anti-HA, DyLight labeling)</td>
			<td>PEPperPRINT</td>
			<td>PPC.037.002</td>
			<td></td>
		</tr>
		<tr>
			<td>PepSLide Analyzer</td>
			<td>PEPperPRINT</td>
			<td>PSA.004.001</td>
			<td>14-days free License for Windows</td>
		</tr>
		<tr>
			<td>Rockland Blocking buffer</td>
			<td>Rockland</td>
			<td>MB-070</td>
			<td></td>
		</tr>
		<tr>
			<td>anti-human IgM (mu chain) DyLight 800</td>
			<td>Rockland</td>
			<td>609-145-007</td>
			<td></td>
		</tr>
		<tr>
			<td>anti-human IgG Fc DyLight 680</td>
			<td>Thermo Scientific</td>
			<td>SA5-10138</td>
			<td></td>
		</tr>
		<tr>
			<td>LI-COR Odyssey Imaging System</td>
			<td>LI-COR</td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>Orbital shaker device</td>
			<td>IKA</td>
			<td>MTS 2/4 digital microtiter shaker</td>
			<td></td>
		</tr>
		<tr>
			<td>Adobe Illustrator</td>
			<td>Adobe</td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>Deltagraph</td>
			<td>Redrocks</td>
			<td></td>
			<td></td>
		</tr>
	</tbody>
</table>

zika virus specific diagnostic epitope discovery

High-density peptide microarrays allow screening of more than six thousand peptides on a single standard microscopy slide. This method can be applied for drug discovery, therapeutic target identification, and developing of diagnostics. Here, we present a protocol to discover specific Zika virus (ZIKV) diagnostic peptides using a high-density peptide microarray. A human serum sample validated for ZIKV infection was incubated with a high-density peptide microarray containing the entire ZIKV protein translated into 3,423 unique 15 linear amino acid (aa) residues with a 14-aa residue overlap printed in duplicate. Staining with different secondary antibodies within the same array, we detected peptides that bind to Immunoglobulin M (IgM) and Immunoglobulin G (IgG) antibodies present in serum. These peptides were selected for further validation experiments. In this protocol, we describe the strategy followed to design, process, and analyze a high-density peptide microarray.

The results obtained using the protocol described are shown in Figure 2 and Figure 3. No background interactions were noted when pre-staining the microarray with secondary anti-human IgM (data not shown). Staining with an anti-human IgM conjugate resulted in several areas above background green fluorescence intensities, indicating the binding of these peptides with IgM in the host serum sample (<strong class="xfi...

Watch this Scientific Journal Video about Zika Virus Specific Diagnostic Epitope Discovery at JoVE.com

Zika Virus Specific Diagnostic Epitope Discovery

In this protocol, we describe a technique to discover Zika virus specific diagnostic peptides using a high-density peptide microarray. This protocol can readly be adapted for other emerging infectious diseases.

High-density peptide microarrays allow screening of more than six thousand peptides on a single standard microscopy slide. This method can be applied for ...

The overall goal of this experiment is to identify Zika virus specific peptides for use in a diagnostic assay to detect Zika virus antibodies. This is critical, as the virus disappears from the blood in approximately 10 days, while antibodies persist for years. This method allows us to identify antigens and epitopes utilizing a microarray of the entire Zika proteome to identify peptides that capture either IgM or IgG antibodies in a sample of serum from an infected individual.The main advantage in detecting both early antibodies, IgM, and later antibodies, IgG, is to provide the clinician a timeline of the infection. And this is particularly important in pregnant women. While this protocol provides insight into the cause of Zika virus infection, it can be applied to other pathogens, using a microarray specific for that pathogen if its protein sequence is known.Handle the glass slide by the edges using powder-free gloves. The glass slide dimensions are 75.4 millimeters by 25.0 millimeters and 1 millimeter thick. Place the slide in the incubation tray with the microarray surface facing up.Fill the empty slide holders with blank slides to prevent the microarray slide from breaking. Place the glossy side of the seal facing downwards onto the microarray printed surface. To ensure a good position, overlap the screw holes of the seal and the base plate.Place the upper part of the tray onto the seal to create a microarray chamber. Secure the slide in the tray by equally tightening the thumb screws one after another by hand in an alternating pattern. Start from the upper left and proceed to the lower right.Place the lid on the incubation tray. Careful handling of the microarray is essential to avoid scratching the microarray surface. Solutions are added to and then removed from the corner of the microarray chamber.Drying the microarray is also important to provide a good scan image. Incubate the microarray with 2, 000 microliters of standard buffer per microarray for 15 minutes at room temperature on an orbital shaker at 140 rpm. Remove the standard buffer by aspirating with a pipette from the corner of the microarray chamber, then block the microarray with a blocking buffer for 60 minutes at room temperature on an orbital shaker at 140 rpm.Remove the blocking buffer by aspirating from the corner of the microarray chamber with a pipette. Add anti-human IgM fluorochrome conjugated secondary antibody diluted 1:5, 000 in the staining buffer to the microarray. Then incubate the microarray for 30 minutes at room temperature in the dark on an orbital shaker at 140 rpm.Use a pipette to remove the secondary antibody by aspirating from the corner of the microarray chamber. Wash the microarray for one minute with 2000 microliters with standard buffer per microarray at room temperature on an orbital shaker at 140 rpm. Remove the standard buffer using the demonstrated technique and repeat the wash two times.Next, immerse the slide twice into 200 milliliters of a freshly prepared dipping buffer. Dry the microarray carefully for approximately one minute by aspirating excess fluid very carefully from the top to the bottom of the slide without touching the slide surface. Analyze the slide in a microarray scanner reader as demonstrated later in this video.Inactivate the serum sample at 56 degrees Celsius for 30 minutes. Then centrifuge the sample at 16, 000 RCF for five minutes at four degrees Celsius. Keep the sample at four degrees Celsius until use.Then incubate the microarray with the staining buffer for 15 minutes at room temperature on an orbital shaker at 140 rpm. Remove the staining buffer by aspirating from the corner of the microarray chamber with a pipette. Dilute the serum sample and staining buffer starting with a 1:1, 000 dilution.Incubate the diluted sample with the microarray overnight at four degrees Celsius on an orbital shaker at 140 rpm. Remove the diluted serum sample using the demonstrated technique. Then wash the microarray three times as before.Dilute the secondary antibody in the staining buffer. Use anti-human IgM fluorochrome conjugated antibody or anti-human IgG fluorochrome conjugated antibody at a dilution of 1:5, 000 in staining buffer. Then mix the control-labeled antibody at a dilution of 1:1000 in staining buffer with the diluted secondary antibody.Incubate with the microarray for 30 minutes at room temperature in the dark and on an orbital shaker at 140 rpm. Remove the mix of diluted secondary and labeled antibodies by aspirating from the corner of the microarray chamber with a pipette. Then wash the microarray three times with standard buffer.Each wash is for one minute on an orbital shaker at 140 rpm. Finally, remove the washing buffer from the microarray chamber as before. To perform microarray scanning, immerse the slide twice into 200 milliliters of freshly prepared dipping buffer.Dry the microarray for around one minute by very carefully aspirating from the top to the bottom of the slide without touching the slide surface. Scan the microarray following the instructions of the scanner. Place the slide onto the scanner with the printed surface facing up.Create a new project and select the scanning area. Set scanner parameters with a resolution of 21 microns, an intensity of 7.0 for both the 700 and 800 nanometer channels, a scanning quality of medium, and an offset of 0.8. Acquire and save the scan draw image as a 16-bit grayscale TIF file format.To analyze the data, open the raw image. Then open the array grid file. Align the array grid to the scan image with the computer's mouse or keyboard arrow keys.Select quantify selection in the specific software, which creates a readout file that contains the signal intensity for each spot, the background value, and the corresponding peptide sequence. Finally, store the microarray sealed in the dark at four degrees Celsius under oxygen-free nitrogen or argon gas. Shown here is the raw fluorescence image of staining the microarray with anti-human IgG after incubating with a specific Zika virus serum sample diluted 1:250.HA control peptides frame the microarray. Peptides that react strongly to IgG are shown in the zoom panel. Similarly, shown here is a raw fluorescence image of staining the microarray with anti-human IgM after incubating with a specific Zika virus serum sample diluted 1:250.Again, the HA control peptides frame the microarray. Peptides that react strongly to IgM are shown in the zoom panel. Shown here is a representative Zika virus epitope consensus sequence reacting with IgM in the host serum sample peptides.Peptides from the epitope consensus sequence are highlighted in red, and the peptide with the highest fluorescence intensity is marked in bold. After watching this video, you should have a good understanding of how to process a high-density peptide microarray. Once mastered, this technique can be done in 24 hours if it is performed properly.While attempting this procedure, it's important to remember to carefully handle the microarray to avoid scratching the microarray surface. Following this procedure, other methods like ELISA or a surface plasmon resonance binding assay can be performed to determine if the identified peptides bind specifically to Zika virus antibodies and not to other Flavivirus antibodies. After its development, this technique will pave the way for researchers in the field of diagnostics for the discovery of diagnostic peptides using serum and saliva specimens.Don't forget that working with infectious agents as Zika virus can be extremely hazardous, and precautions such as heat-inactivating the serum sample and working in Biosafety Level 2 facilities should always be taken while performing this procedure.

zika-virus-specific-diagnostic-epitope-discovery

Research

JoVE Journal

Immunology and Infection

7.6K Görüntüleme.  New York University College of Dentistry. The overall goal of this experiment is to identify Zika virus specific peptides for use in a diagnostic assay to detect Zika virus antibodies. This is critical, as the virus disappears from the blood in approximately 10 days, while antibodies persist for years. This method allows us to identify antigens and epitopes utilizing a microarray of the entire Zika proteome to identify peptides that capture either IgM or IgG antibodies in a sample of serum from an infected individual.The main ...